Treating Dry Eye: Start With the Target

Because two people can both have dry-eye disease while having very different problems underneath it. One person may have severely obstructed meibomian glands. Another may produce too little aqueous tear fluid. Another may have significant ocular-surface inflammation. Another may not close their eyelids completely during sleep. Another may have severe tear-film instability related to blinking. Another may have an important neural component to their symptoms. And many people have several of these problems at the same time.

This is one of the major ideas behind the modern approach to dry-eye management. TFOS DEWS III emphasizes identifying the etiological drivers of an individual’s dry eye so treatment can be directed toward the relevant subtype or subtypes.

Being diagnosed with dry-eye disease tells you that there is a problem with tear-film and/or ocular-surface homeostasis. But it does not yet tell you everything you need to know about treatment.

Think about what we did in the previous sections of this guide. We asked:

• •Is the lipid component deficient or abnormal?
• •Is aqueous tear production reduced?
• •Is the tear film unstable?
• •Are the meibomian glands functioning normally?
• •Is blinking complete?
• •Are the eyelids closing properly?
• •Is the ocular surface damaged or inflamed?
• •Could neural dysfunction be contributing?

Those questions were not just about getting a more precise diagnosis. They matter because the answers can change the treatment.

How Dry Eye Is Diagnosed: how those questions get answered

Imagine that testing shows severe meibomian gland obstruction. Treatments designed to improve meibomian gland function may make sense.

Now imagine instead that the meibomian glands are functioning reasonably well, but aqueous tear production is severely reduced. That is a different problem. Repeatedly treating the meibomian glands would not directly correct the aqueous deficiency.

Or imagine that someone’s main problem is incomplete eyelid closure during sleep. They may use increasingly sophisticated eye drops without addressing the fact that part of the ocular surface remains exposed for hours every night.

This is why a treatment can be effective for dry eye and still be the wrong treatment for your dry eye.

A treatment target is the specific abnormality you are trying to change. For example:

• •Target: obstructed or poorly functioning meibomian glands. Possible strategies may include heat, expression or selected in-office MGD treatments.
• •Target: inadequate aqueous tears. Management may focus on supplementing tears, conserving existing tears or stimulating tear production.
• •Target: clinically important inflammation. Anti-inflammatory treatment may be appropriate.
• •Target: ocular-surface damage or inadequate protection. Lubrication, biologic tear substitutes or protective strategies may become important.
• •Target: eyelid exposure. The priority may be protecting the exposed surface and addressing the eyelid problem.
• •Target: neural dysfunction or persistent ocular pain. Management may need to extend beyond conventional tear-film treatment.

These categories can overlap. The purpose is not to put every patient into one box. It is to understand why each treatment is being used.

No. This distinction is important. Dry-eye testing can reveal several abnormalities, but finding an abnormality does not automatically mean it needs its own aggressive treatment. The clinician has to interpret:

• •how abnormal it is
• •whether it fits the rest of the clinical picture
• •whether it is likely to be contributing to symptoms or surface damage
• •whether treating it is likely to provide meaningful benefit

Otherwise, dry-eye management can become a process of treating every imperfect number or image rather than treating the patient.

That is extremely common. Dry eye is a multifactorial disease, and different mechanisms can coexist. The current TFOS DEWS III classification specifically separates potential drivers involving tear-film deficiencies, eyelid abnormalities and ocular-surface abnormalities rather than forcing every patient into a single category. For example, someone might have:

• •MGD + incomplete blinking + inflammation
• •aqueous deficiency + MGD
• •exposure + tear-film instability + surface damage

In those situations, combination treatment may make sense. But there is an important difference between using several treatments because several relevant targets have been identified, and using several treatments because nothing has worked yet. Those are not the same strategy.

Dry Eye Is Often Mixed: why several problems coexist

Not necessarily. Dry eye can become frustrating precisely because there are so many available treatments. When symptoms continue, the temptation is to keep adding:

• •another drop
• •another supplement
• •another procedure
• •another device

Sometimes combination therapy is appropriate. But every additional treatment also brings potential cost, time, burden and side effects — and sometimes additional irritation to an already sensitive ocular surface.

The TFOS DEWS III management report includes a wide range of approaches — from tear supplementation and conservation to MGD treatment, anti-inflammatory therapy, biologic tears, environmental modification and advanced interventions. Importantly, its prescribing framework is intended to guide treatment according to disease etiology rather than imply that every patient should progress through every available treatment.

This sounds obvious. But it is surprisingly easy to lose sight of it.

Ask: what exactly are we trying to change with IPL in my case?

Ask: what evidence do we have that my glands are obstructed or their secretion is abnormal?

Ask: what suggests that inflammation is an important treatment target?

Ask: why are we trying to conserve tears, and what do my tear-volume findings show?

This does not mean patients need to challenge every recommendation. It means you should be able to understand the logic connecting the finding, the target and the treatment.

finding→target→treatment

“IPL.” “Cyclosporine.” “Warm compresses.” “Serum tears.” Those are interventions. A treatment plan requires more information. Ideally, you should understand:

• •What are we treating?
• •Why do we think this is part of my dry eye?
• •What should this treatment change?
• •How long might that change take?
• •How will we know whether it worked?

Without those answers, it can become very difficult to interpret what happens next.

Suppose you begin treatment for MGD. What would success look like? Less discomfort? Better tolerance of screens? Improved meibum quality? More expressible glands? Better tear-film stability? Less staining? Some combination of these? Different treatments may affect different outcomes, and symptoms and clinical signs do not always change at the same speed.

So before deciding that a treatment “worked” or “failed,” it helps to know what you expected it to accomplish.

Not every dry-eye treatment works on the same timeline. Some interventions may provide relatively rapid symptomatic relief. Others are intended to change inflammation, gland function or ocular-surface health over weeks or months.

That means “I tried it and it didn’t work” is difficult to interpret unless we know:

• •what was used
• •how it was used
• •for how long
• •what outcome was expected

At the same time, “it needs more time” should not become an unlimited explanation for continuing a treatment that is ineffective, poorly tolerated or causing problems. There should be a reason for continuing it.

A failed treatment can provide information — but only if we interpret it carefully. Instead of immediately concluding:

“My dry eye is untreatable.”

there are several different possibilities. Perhaps the treatment target was correct, but the treatment was insufficient. Perhaps it was not used long enough. Perhaps adherence was difficult. Perhaps another untreated driver is still active. Perhaps the original target was not actually the main problem. Or perhaps the treatment simply does not work well for that individual.

This is where reassessment becomes important.

How to Choose a Dry Eye Treatment: reassessing and choosing what comes next

If heat and expression improve meibomian secretion, that supports the idea that gland dysfunction was clinically relevant. If reducing environmental exposure dramatically improves symptoms, environmental stress was probably an important contributor. But treatment response should not be used backwards as absolute proof of diagnosis. For example:

“IPL helped me, therefore ocular rosacea caused my dry eye.”

That would be too strong. One intervention may affect several biological pathways, symptoms can fluctuate naturally and dry eye often contains multiple overlapping mechanisms.

Treatment response is another piece of evidence. It is not the whole diagnosis.

That can happen. And the reverse can happen too. A clinical measurement may improve while the patient still feels terrible. Dry-eye disease is particularly challenging because symptoms and signs can be poorly correlated in some people.

So treatment success should not necessarily be reduced to one number. Depending on the individual, meaningful improvement might include:

• •less pain
• •longer screen tolerance
• •better vision stability
• •less need for drops
• •better outdoor tolerance
• •improved ocular-surface findings
• •measurable improvement in the specific mechanism being treated

Real-life function matters.

Sometimes both. Symptom relief is not somehow less legitimate than treating an underlying mechanism. If lubrication makes someone significantly more comfortable, that matters. Protecting the ocular surface also matters while the underlying problem is being investigated or treated.

But supportive treatment and disease-targeted treatment are not always the same thing. Artificial tears, for example, may improve lubrication and temporarily support the tear film without correcting the reason the tear film became unstable. That does not make them useless. It simply means we should understand their role.

Artificial Tears & Dry Eye Drops: what lubrication does and does not do

Yes. Any treatment can have disadvantages. Drops may irritate some eyes. Preservatives can become problematic with frequent exposure. Heat can irritate eyelid skin. Procedures can have side effects. Contact lenses or devices may not be tolerated. Systemic or topical medications can have risks.

This is why treatment decisions are always a balance between expected benefit on one side and burden, risk and uncertainty on the other. A treatment does not become harmless simply because it is marketed for dry eye.

Dry eye is an active area of research, and new devices, medications and procedures continue to appear. That can be exciting. But “new” and “advanced” do not automatically mean “better.” When evaluating a treatment, useful questions include:

• •What mechanism is it supposed to affect?
• •Has that mechanism actually been identified in me?
• •What evidence supports the treatment?
• •Which patients were studied?
• •What outcomes improved?
• •How large was the improvement?
• •How long did it last?
• •What are the risks and limitations?

We will use exactly this approach throughout the treatment section of this guide.

You may notice that the next articles are not simply one enormous list of dry-eye treatments. Instead, we will move through the system. We will look at treatments aimed at:

• •meibomian glands and the lipid component
• •aqueous tears
• •inflammation
• •ocular-surface protection
• •eyelid and exposure problems
• •neural symptoms and pain

That structure is intentional. The current TFOS DEWS III approach similarly emphasizes identifying etiological drivers and linking them to appropriate management rather than treating DED as one uniform disease.

Treating Meibomian Gland Dysfunction: the first target we will look at